Function of microRNA‑141 in human breast cancer through cytotoxic CD4+ T cells regulated by MAP4K4 expression

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Breast cancer is a leading cause of mortality worldwide.
• MicroRNA-141 (miRNA-141) is frequently downregulated in breast cancer patients.
• Understanding miRNA-141's role is crucial for developing novel breast cancer therapies.

Purpose of the Study:

• To investigate the anti-cancer effects of miRNA-141 on breast cancer cell apoptosis.
• To elucidate the underlying molecular mechanisms of miRNA-141's action.
• To explore the relationship between miRNA-141, inflammatory markers, and immune cell activity.

Main Methods:

• Assessing miRNA-141 expression levels in breast cancer.
• Manipulating miRNA-141 expression (overexpression and downregulation) in breast cancer cell lines (MCF-7).
• Measuring apoptosis rates, inflammatory markers (COX-2, PGE2, TNF-α, IL-10), MAP4K4 protein expression, and CD4+ T cell toxicity.

Main Results:

• Downregulation of miRNA-141 observed in breast cancer patients.
• miRNA-141 overexpression reduced cell growth, inhibited COX-2, PGE2, TNF-α, and increased IL-10.
• miRNA-141 suppressed MAP4K4 expression, which in turn enhanced CD4+ T cell-mediated breast cancer cell toxicity.

Conclusions:

• miRNA-141 demonstrates significant anti-tumor effects in human breast cancer cells.
• The anti-cancer mechanism involves modulation of inflammatory pathways and MAP4K4 expression.
• miRNA-141 enhances anti-tumor immunity via cytotoxic CD4+ T cells, suggesting therapeutic potential.